← The Wire
AVBPNasdaq
ArriVent BioPharma, Inc.
Pharmaceutical Preparations · DE · CIK 1868279
ArriVent BioPharma develops and commercializes differentiated medicines for unmet cancer needs, focusing on firmonertinib and novel therapeutics
$1.42B
Market cap
$34.37
Last close
+1.1%
1D
+5.1%
5D
486K
Volume
Price · last 39 sessions+13.1%
May 4L $26.15 · H $34.37Jun 29
58
Total filings
Jun 22, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 22, 20268-KCompany UpdateMay 11, 2026424B5424B5May 11, 202610-Q10-QMay 11, 20268-KResults of OperationsMay 11, 2026DEFA14ADEFA14AApr 28, 2026DEF 14AFORM- DEF 14AApr 28, 20268-KReg FD Disclosure · Company UpdateMar 17, 202610-K10-KMar 5, 20268-KResults of OperationsMar 5, 202610-Q10-QNov 10, 20258-KResults of OperationsNov 10, 20258-KReg FD Disclosure · Company UpdateSep 9, 202510-Q10-QAug 11, 20258-KResults of OperationsAug 11, 20258-KCompany UpdateJul 21, 2025424B5424B5Jul 2, 20258-KMaterial Agreement · Company UpdateJul 2, 2025424B5424B5Jul 1, 20258-KReg FD Disclosure · Company UpdateJun 23, 20258-KShareholder VoteJun 20, 202510-Q10-QMay 12, 20258-KResults of OperationsMay 12, 2025DEFA14ADEFA14AApr 28, 2025DEF 14ADEF 14AApr 28, 20258-KExecutive Change · Reg FD DisclosureApr 28, 20258-KAuditor ChangeMar 13, 20258-KResults of OperationsMar 3, 202510-K10-KMar 3, 20258-KMaterial Agreement · Reg FD DisclosureJan 22, 2025SC 13GSC 13GDec 4, 2024SC 13GARRIVENT BIOPHARMA, INC.Nov 14, 202410-Q10-QNov 14, 20248-KResults of OperationsNov 14, 2024SC 13GSC 13GNov 12, 2024SC 13GSC 13GNov 12, 2024SC 13GSC 13GNov 8, 2024SC 13GSC 13GOct 24, 2024SC 13GSC 13GOct 11, 20248-KReg FD Disclosure · Company UpdateSep 9, 202410-Q10-QAug 14, 20248-KResults of OperationsAug 14, 20248-K/AExecutive ChangeJul 9, 20248-K/AExecutive ChangeJul 9, 20248-KMaterial Agreement · Reg FD DisclosureJun 5, 20248-KExecutive ChangeMay 16, 202410-Q10-QMay 8, 20248-KResults of OperationsMay 8, 20248-KExecutive ChangeApr 22, 202410-K10-KMar 28, 20248-KResults of OperationsMar 28, 2024SC 13GSCHEDULE 13GFeb 13, 2024SC 13DSCHEDULE 13DFeb 5, 20248-KBylaw Amendment · Company UpdateJan 30, 2024424B4424B4Jan 26, 2024S-1/AS-1/AJan 23, 2024S-1/AS-1/AJan 22, 2024S-1S-1Jan 5, 2024
Insider Activity
In the 90 days to Dec 10, 2025: 1 sold $13.0M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 10, 2025 | Hhlr Advisors, Ltd.TenPercentOwner | Sell | 555,555 | $23.37 | $13.0M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance